GlassScriptPhysician profile
Jill Shimabuku
NPI 1811403165
$3,663.03
in general payments reported to CMS, 2019-2025
27 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $973 · 2024: $945 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,115 · Education: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,115.09 |
| Education | $547.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $570.96 | 2023-2025 | Xtandi, Vyloy |
| Janssen Biotech, INC. | $440.76 | 2023-2025 | Carvykti, Rybrevant, Darzalex |
| Astrazeneca Pharmaceuticals LP | $420.02 | 2023-2025 | Imfinzi, Enhertu, Datroway |
| Exelixis INC. | $287.18 | 2023-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $265.06 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $261.10 | 2023-2025 | Keytruda, Lynparza, Lenvima |
| Abbvie INC. | $223.60 | 2024-2025 | |
| Pfizer INC. | $175.17 | 2023-2025 | |
| Eisai INC. | $161.53 | 2023-2024 | |
| Incyte Corporation | $123.59 | 2024 | Monjuvi, Pemazyre |
| Karyopharm Therapeutics INC. | $93.72 | 2023-2025 | Xpovio |
| Seagen INC. | $80.00 | 2025 | |
| Daiichi Sankyo INC. | $74.99 | 2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $64.12 | 2023-2024 | Ninlaro, Alunbrig |
| Regeneron Healthcare Solutions, INC. | $60.16 | 2023-2025 | Libtayo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $54.34 | 2023 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $50.40 | 2023-2025 | Odomzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.89 | 2024-2025 | Gilotrif |
| E.R. Squibb & Sons, L.L.C. | $31.32 | 2023 | Opdivo |
| Aveo Pharmaceuticals, INC. | $30.39 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $27.07 | 2023 | Somatuline Depot, Onivyde |
| Coherus Oncology, INC. | $24.20 | 2025 | Loqtorzi |
| Genzyme Corporation | $22.36 | 2024 | |
| Taiho Oncology, INC. | $20.47 | 2025 | |
| Blueprint Medicines Corporation | $19.09 | 2023 | Ayvakit |
| Celgene Corporation | $18.85 | 2025 | Opdivo |
| Kyowa Kirin, INC. | $13.69 | 2023 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Shimabuku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.